SCHEMBL1905178

SCHEMBL1905178

NC(=O)c1nccc(-c2ccccc2)c1N1CCCC1c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.43
PIK3C3 Q8NEB9 1/20 0.43
NR3C2 P08235 1/20 0.41
SCD5 Q86SK9 4/20 0.39
SCD O00767 3/20 0.39
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
CDC42BPB Q9Y5S2 1/20 0.39
RIPK1 Q13546 1/20 0.38
MAPK14 Q16539 1/20 0.38
PDE10A Q9Y233 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRK1 P41145 1/20 0.37
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1905180 0.82 NUDT1 (0.51) NUDT1PIK3C3NR3C2SCD5SCD
SCHEMBL1900466 0.74 ADORA2A (0.38)
SCHEMBL1908175 0.71 BCAT2 (0.36)
SCHEMBL29959318 0.70 ADORA2A (0.39)
SCHEMBL3971163 0.70 ADORA2A (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL979249 0.69 MAPK9 (0.38) ROCK1
SCHEMBL23248737 0.68 PTPN11 (0.45)
SCHEMBL944492 0.68 ROCK2 (0.46) ROCK2ROCK1CDC42BPB
SCHEMBL23067311 0.67 MAP2K3 (0.50)
SCHEMBL2848953 0.67 ADORA2A (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRM4, GRIA4, GRIK4 NUDT1 2666/4885PIK3C3 4035/4885NR3C2 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.